168 related articles for article (PubMed ID: 28733701)
1. Copper (II) complexes of bidentate ligands exhibit potent anti-cancer activity regardless of platinum sensitivity status.
Wehbe M; Lo C; Leung AWY; Dragowska WH; Ryan GM; Bally MB
Invest New Drugs; 2017 Dec; 35(6):682-690. PubMed ID: 28733701
[TBL] [Abstract][Full Text] [Related]
2. Platinum(II) and Copper(II) complexes of asymmetric halogen-substituted [NN'O] ligands: Synthesis, characterization, structural investigations and antiproliferative activity.
Amiri Rudbari H; Saadati A; Aryaeifar M; Blacque O; Cuevas-Vicario JV; Cabral R; Raposo LR; Fernandes AR
Bioorg Chem; 2022 Feb; 119():105556. PubMed ID: 34959175
[TBL] [Abstract][Full Text] [Related]
3. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
4. Cellular pharmacology of cis and trans pairs of platinum complexes in cisplatin-sensitive and -resistant human ovarian carcinoma cells.
O'Neill CF; Hunakova L; Kelland LR
Chem Biol Interact; 1999 Nov; 123(1):11-29. PubMed ID: 10597899
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and antiproliferative activity of hindered, chiral 1,2-diaminodiamantane platinum(II) complexes.
Bakhonsky VV; Pashenko AA; Becker J; Hausmann H; De Groot HJM; Overkleeft HS; Fokin AA; Schreiner PR
Dalton Trans; 2020 Oct; 49(40):14009-14016. PubMed ID: 33078783
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells.
Samimi G; Safaei R; Katano K; Holzer AK; Rochdi M; Tomioka M; Goodman M; Howell SB
Clin Cancer Res; 2004 Jul; 10(14):4661-9. PubMed ID: 15269138
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and in vitro and in vivo antitumor activity of a series of trans platinum antitumor complexes.
Kelland LR; Barnard CF; Evans IG; Murrer BA; Theobald BR; Wyer SB; Goddard PM; Jones M; Valenti M; Bryant A
J Med Chem; 1995 Aug; 38(16):3016-24. PubMed ID: 7636864
[TBL] [Abstract][Full Text] [Related]
8. Dinuclear platinum complexes with N, N'-bis(aminoalkyl)-1,4-diaminoanthraquinones as linking ligands. Part II. Cellular processing in A2780 cisplatin-resistant human ovarian carcinoma cells: new insights into the mechanism of resistance.
Kalayda GV; Jansen BA; Molenaar C; Wielaard P; Tanke HJ; Reedijk J
J Biol Inorg Chem; 2004 Jun; 9(4):414-22. PubMed ID: 15071768
[TBL] [Abstract][Full Text] [Related]
9. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
Deqnah N; Yu JQ; Beale P; Fisher K; Huq F
Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298
[TBL] [Abstract][Full Text] [Related]
10. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
11. Platinum (IV)-fatty acid conjugates overcome inherently and acquired Cisplatin resistant cancer cell lines: an in-vitro study.
Ratzon E; Najajreh Y; Salem R; Khamaisie H; Ruthardt M; Mahajna J
BMC Cancer; 2016 Feb; 16():140. PubMed ID: 26906901
[TBL] [Abstract][Full Text] [Related]
12. Synthesis of trans-(4-hydroxypyridine)(ammine)dichloroplatinum(II) and its activity in the human ovarian tumour models.
Deqnah N; Qing Yu J; Beale P; Fisher K; Huq F
Med Chem; 2013 Jun; 9(4):539-44. PubMed ID: 23061563
[TBL] [Abstract][Full Text] [Related]
13. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
14. A hybrid platinum drug dichloroacetate-platinum(II) overcomes cisplatin drug resistance through dual organelle targeting.
Zhang Y; Guo G; Ma B; Du R; Xiao H; Yang X; Li W; Gao Y; Li Y; Jing X
Anticancer Drugs; 2015 Aug; 26(7):698-705. PubMed ID: 25811961
[TBL] [Abstract][Full Text] [Related]
15. A novel trans-platinum coordination complex possessing in vitro and in vivo antitumor activity.
Kelland LR; Barnard CF; Mellish KJ; Jones M; Goddard PM; Valenti M; Bryant A; Murrer BA; Harrap KR
Cancer Res; 1994 Nov; 54(21):5618-22. PubMed ID: 7923207
[TBL] [Abstract][Full Text] [Related]
16. Platinum(II) carboxylato complexes containing 7-azaindoles as N-donor carrier ligands showed cytotoxicity against cancer cell lines.
Štarha P; Trávníček Z; Pazderová L; Dvořák Z
J Inorg Biochem; 2016 Sep; 162():109-116. PubMed ID: 27350081
[TBL] [Abstract][Full Text] [Related]
17. Disulfiram Copper Nanoparticles Prepared with a Stabilized Metal Ion Ligand Complex Method for Treating Drug-Resistant Prostate Cancers.
Chen W; Yang W; Chen P; Huang Y; Li F
ACS Appl Mater Interfaces; 2018 Dec; 10(48):41118-41128. PubMed ID: 30444340
[TBL] [Abstract][Full Text] [Related]
18. Square planar Au(III), Pt(II) and Cu(II) complexes with quinoline-substituted 2,2':6',2″-terpyridine ligands: From in vitro to in vivo biological properties.
Choroba K; Machura B; Szlapa-Kula A; Malecki JG; Raposo L; Roma-Rodrigues C; Cordeiro S; Baptista PV; Fernandes AR
Eur J Med Chem; 2021 Jun; 218():113404. PubMed ID: 33823390
[TBL] [Abstract][Full Text] [Related]
19. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
20. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.
Wehbe M; Anantha M; Shi M; Leung AW; Dragowska WH; Sanche L; Bally MB
Int J Nanomedicine; 2017; 12():4129-4146. PubMed ID: 28615941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
